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Phosphate concentration in artificial tears
Abstract Background: Irrigating
solutions and eye drops may contain
phosphates as part of their buffer
system. In the presence of epithelial
keratopathy, a high concentration of
phosphate favours corneal calcifica-
tion. Knowledge of the phosphate
concentration in artificial tear prod-
ucts helps to prevent this sight-
threatening complication. This study
gives an overview on the amount of
phosphate contained in artificial tears.
Methods: Fifty-nine samples of
commercially available artificial tear
preparations were tested. The quanti-
fication of phosphate was performed
using the molybdate method on a
Modular P autoanalyzer. Results:
Twenty-six of 59 (44%) artificial tear
products had a phosphate concentra-
tion above physiological levels
(>1.45 mmol/l). A phosphate con-
centration above 25 mmol/l was
found in nine products (15%), a
concentration higher than 50 mmol/l
in three (5%). Conclusions: Many
artificial tear formulations contain
unphysiological levels of phosphate,
but very high concentrations are
found only in a few products. These
preparations have the potential to
favour the formation of insoluble
crystalline calcium phosphate depos-
its when used on a damaged corneal
surface, and should therefore be
used cautiously.
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Introduction
Eye drop preparations typically consist of a pharmaceuti-
cally active drug, a preservative and a vehicle [2]. Potential
side effects of the active drug have been studied system-
atically [4]. The toxic effects of preservatives have also
been recognised [3]. Little attention has been given so far to
the role of vehicles in the development of ocular adverse
effects.
An ophthalmic vehicle is an agent other than the active
drug or preservative that is added to a formulation to
provide proper tonicity, buffering, and viscosity to com-
plement drug action. The buffering system may consist of
acetic, boric and hydrochloric acid, and of potassium or
sodium bicarbonate, borate, phosphate and citrate [2]. In
many eye drops, the buffering system consists of phos-
phates. The phosphate is typically introduced in the form of
disodium hydrogen phosphate dodecahydrate or sodium
dihydrogen phosphate dihydrate. Recent studies have
shown that a high concentration of phosphate buffer may
cause irreversible corneal calcification with visual loss.
Daly et al. reported rapid corneal calcification after
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Table 1 Phosphate concentration in commercially available artificial tear preparations, German and Swiss market
Market Phosphate, PO4–
Germany (GER)
Switzerland (CH)
mmol/l
Hydroxypropyl methylcellulose (HPMC)
Artelac–EDO, Gerhard Mann Gmbh GER 18.2
Berberil Drye Eye–EDO, Gerhard Mann Gmbh GER 3.3
GenTeal, Novartis Opthalmics GER <0.1
Isopto Tears, Alcon CH 60.6
Lacrigel sine, Winzer GER 0.4
Sicca–Stulln, Pharma Stulln GER <0.1
Sic–Ophtal sine, Winzer GER 18.5
Tears Naturale, Alcon CH <0.1
Carboxyl methylcellulose (CMC)
Cellufluid, Allergan CH <0.1
Cellufresh, Pharm–Allergan GER <0.1
Cellumed, Pharm–Allergan GER <0.1
Celluvisc UD, Allergan GER, CH <0.1
Polyvinyl alcohol (PVA)
Collylarm, Vifor CH <0.1
Hypo Tears, Novartis Ophthalmics CH <0.1
Lacrimal OK, Pharm–Allergan GER <0.1
Liquifilm N, Pharm–Allergan GER 28.8
Liquitears, Allergan CH 29.7
Vistil, Santen GER 11.2
Polyvidone
Arufil uno, Chauvin ankerpharm GER <0.1
Lacopthal sine, Winzer GER <0.1
Lacri–Stulln DU, Pharma Stulln GER 68.8
Oculac, Novartis Ophthalmics GER, CH <0.1
Protagent SE, Alcon GER, CH <0.1
Vidirakt S mit PVP, Gerhard Mann Gmbh GER <0.1
Vidisept EDO, Gerhard Mann Gmbh GER <0.1
Vidisic EDO, Gerhard Mann Gmbh GER <0.1
Yxin Tears ED, Pfizer GER <0.1
Wet–Comod, Ursapharm GER 5.7
Glycerine
Systane, Alcon GER, CH <0.1
Dextran
Dialens, Bausch & Lomb CH <0.1
Carbomer980
Lacrinorm UD, Bausch & Lomb CH 11.8
Liposic EDO, Gerhard Mann Gmbh GER <0.1
Vidisic EDO, Gerhard Mann Gmbh GER <0.1
Viscotears SDU, Novartis Ophthalmics CH <0.1
Carbomer 974
Lacryvisc SE, Alcon CH <0.1
Siccafluid, Thea Pharma CH <0.1
Sodium hyaluronate
Biolan, Santen GER 2.1
Comfort Shield UD, i.com medical GmbH GER, CH 2.3
Fermavisc UD, Novartis Ophthalmics CH 1.7
Hyabak, Laboratoires Théa, France CH 10.9
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irrigation with phosphate-buffered saline [5]. Similar de-
posits were described after ocular surface disease and
frequent use of phospate-buffered hyaluronic acid artificial
tears [1].
Information on phosphate concentrations in artificial tear
preparations will help clinicians caring for patients at risk
for corneal calcification. This study examines the artificial
tear preparations that are currently available in Germany
and/or Switzerland.
Materials and methods
All the artificial tear preparations that are listed as drop
preparations in the “Rote Liste 2005” (Rote Liste Service
GmbH, Frankfurt/Main, Editio Cantor Verlag, Aulendorf,
Germany) and the “Arzneimittelkompendium der Schweiz
2005” (Documed AG, Basel, Switzerland) were included
in this study. When the preparations were available in
multidose and unit dose containers, the samples were taken
from the preservative-free formulation. For technical
reasons, gel preparations were not included. The quantifica-
tion of the phosphate was performed with the molybdate
method on a Modular P autoanalyzer (Roche Diagnostics,
Basel, Switzerland) [7]. The results were compared to the
physiological concentrations published elsewhere [7, 8].
Results
The phosphate concentrations of the ocular therapeutics
that were studied are listed in Table 1. Table 2 gives an
overview of the artificial tears that showed concentrations
above physiological levels.
Twenty-six of 59 (44%) of the tested artificial tear
products showed a phosphate concentration above physi-
ological levels (>1.45 mmol/l). Concentrations above
25 mmol/l were found in nine products (15%), and high
levels above 50 mmol/l in three (5%). There was no
correlation between the type of product and the phosphate
concentration. The three products with high phosphate
concentrations included lubricants based on polyvidone
(Lacri-Stulln DU, Pharma Stulln, Germany), hydroxylpro-
pyl methylcellulose (Isopto Tears, Alcon) and sodium hya-
luronate (Hylo-Comod, Ursapharm, Germany). Twelve of
15 hyaluronate preparations were buffered with phosphate.
Table1 (continued)
Market Phosphate, PO4–
Germany (GER)
Switzerland (CH)
mmol/l
Hyal–drop, Bausch & Lomb CH 2
HycoSan5, Pharma Medica CH 48.7
Hylan, Pharma Stulln GER <0.1
Hylo–Comod, Ursapharm GER, CH 50.9
Hylo–Vision, OmniVision GER 1.9
Oxyal, Santen GER <0.1
Vislube, TRB chemedica GER, CH 9.9
Vismed Gel UD, TRB chemedica GER, CH 10.8
Vismed UD, TRB chemedica GER, CH 10.5
Vismed light, TRB chemedica GER, CH 1.9
Xidan EDO, Gerhard Mann Gmbh GER <0.1
Combinations
Dispatenol, Novartis Ophthalmics (dexapanthnol, polyvinylacohol) GER 44.3
Hylo–Care, Ursapharm (sodium hyaluronate, dexapanthenol) GER 25.6
Isopto–Naturale, Alcon (hypromellose, dextran) GER <0.1
Lacrimal O.K., Pharm–Allergan (polyvinylalcohol, polyvidone) GER <0.1
Lacrisic, Alcon (hypromellose, polyvidone, glycerol) GER 15.1
Lacrycon UD, Thea Pharma (sodium hyaluronate, glycerine, Carbomer 981) CH <0.1
Oculotect sine, Novartis Ophthalmics (retinolpalmitate, hypromellose) GER 0.1
Siccaprotect, Ursapharm (dexapanthenol, polyvinylalcohol) GER 44.3
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Discussion
The constituents of topical medications change the
composition of the precorneal tear film. The phosphate
concentration may be increased by the vehicle of ophthal-
mic preparations. Phosphates are widely used as part of
buffering systems and were found in many of the artificial
tear products in this series.
Recent studies have shown that phosphate buffers play a
role in the process of corneal calcification [1, 5, 6, 8, 10].
Calcification occurs when calcium cations and phosphate
anions form insoluble crystals within the tissue. In the
cornea, deposition typically occurs as hydroxyapatite
Ca5(PO4)3OH [1, 5, 9]. (Fig. 1). Deposition of calcium
can be observed as a spectrum of clinical findings, ranging
from subtle age-related superficial changes to full-thick-
ness calcification of the entire cornea with visual loss.
Forty-five percent of the tested artificial tear products
had a phosphate concentration above physiological levels
(>1.45 mmol/l). High concentrations (above 25 mmol/l)
were only found in nine products. To date, it is not clear
which is the critical concentration of phosphate with regard
to the onset of corneal calcification. In the animal model,
rapid corneal calcification developed after alkali eye burns
with large epithelial defects when the eyes were irrigated
with Isogutt (Dr. Winzer Pharma GmbH, Germany) [10]. In
Table 2 Artificial tear products with phosphate concentrations above physiological levels (>1.45 mmol/l)
Market Phosphate, PO4–
Germany (GER) Switzerland (CH) mmol/l
Lacri–Stulln DU, Pharma Stulln (polyvidone) GER 68.8
Isopto Tears, Alcon (hypromellose) CH 60.6
Hylo–Comod, Ursapharm (sodium hyaluronate) GER, CH 50.9
HycoSan5, Pharma Medica (sodium hyaluronate) CH 48.7
Siccaprotect, Ursapharm (dexapanthenol, polyvinyl alcohol) GER 44.3
Dispatenol, Novartis Opthalmics (dexapanthnol, polyvinyl alcohol) GER 44.3
Liquitears, Allergan (polyvinyl alcohol) CH 29.7
Liquifilm N, Pharm–Allergan (polyvinyl alcohol) GER 28.8
Hylo–Care, Ursapharm (sodium hyaluronate, dexapanthenol) GER 25.6
Sic–Ophtal sine, Winzer (hypromellose) GER 18.5
Artelac–EDO, Gerhard Mann Gmbh (hypromellose) GER 18.2
Lacrisic, Alcon (hypromellose, polyvidone, glycerol) GER 15.1
Lacinorm UD, Bausch & Lomb (carbomer 980) CH 11.8
Vistil, Santen (polyvinyl alcohol) GER 11.2
Hyabak, Laboratoires Théa, France (sodium hyaluronate) CH 10.9
Vismed Gel UD, TRB chemedica (0.3% sodium hyaluronate) GER, CH 10.8
Vismed UD, TRB chemedica (0.18% sodium hyaluronate) GER, CH 10.5
Vislube, TRB chemedica (sodium hyaluronate) GER, CH 9.9
Wet–Comod, Ursapharm (polyvidone) GER 5.7
Berberil Drye Eye–EDO, Gerhard Mann Gmbh (polyvidone) GER 3.3
Comfort Shield UD, i.com medical GmbH (sodium hyaluronate) GER, CH 2.3
Biolan, Santen (sodium hyaluronate) GER 2.1
Hyal–drop, Bausch & Lomb (sodium hyaluronate) CH 2
Vismed light, TRB chemedica (0.1% sodium hyaluronate) GER, CH 1.9
Hylo–Vision, OmniVision (sodium hyaluronate) GER 1.9
Fermavisc UD, Novartis (sodium hyaluronate) CH 1.7
Fig. 1 Formation of a calcified plaque on intensified treatment with
phosphate-buffered hyaluronate artificial tears. A chemical burn had
led to a complete corneal erosion that was treated with a therapeutic
contact lens and hyaluronate eye drops containing 50.9 mmol/l
phosphate. The large area of calcification developed within 3 days
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this solution, a phosphate concentration of 148 mol/l was
measured.
The use of artificial tears for the treatment of epithelial
keratopathy or erosions may lead to similar conditions to
those in the animal model: With epithelial defects, the
drops are typically applied very frequently, and the
phosphate-rich lubricants may push the ion product
towards precipitation. In addition, the viscous character
of many artificial tears may prolong exposure time to the
phosphates.
It is beyond doubt that very high topical phosphate
concentrations have an impact on the process of corneal
calcification. Corneal calcification, however, is dependent
on many variables. These include pH, tonicity, size of
epithelial defect, and amount of barrier dysfunction [8, 10].
Therefore, the definition of a critical phosphate concentra-
tion is difficult. Further studies are required to allow
rational recommendations. In the series with calcification
following ocular surface disease and intensified use of
hyaluronic acid artificial tears [1], the concentration in the
lubricant was 50.9 mmol/l, which may serve as a first idea.
When artificial tears are used for the treatment of
epithelial defects, phosphate-free or preparations with low
phosphate concentrations are preferable. This overview
helps the clinician in the selection. The pharmaceutical
industry is encouraged to develop phosphate-free prepara-
tions for this indication.
References
1. Bernauer W, Thiel MA, Kurrer M,
Heiligenhaus A, Rentsch KM, Schmitt
A, Heinz C, Yanar A (2005) Corneal
calcification following intensified
treatment with sodium hyaluronate
artificial tears. Br J Ophthalmol
doi: http://10.1136/bjo.2005.082792
2. Burstein NL (1995) Ophthalmic drug
formulations. In: Bartlett DJ, Jaanus SD
(eds) Clinical ocular pharmacology.
Butterworth-Heinemann, Boston Ox-
ford Melbourne Singapore Toronto
Munich New Delhi Tokyo, pp 21–45
3. Burstein NL (1980) Corneal
cytotoxicity of topically applied drugs,
vehicles and preservatives. Surv
Ophthalmol 25:15–30
4. Fraunfelder FT, Fraunfelder W; as-
sociate editor, Randall JA (2001) Drug-
induced ocular side effects, 5th edn.
Butterworth-Heinemann, Boston
Oxford Auckland Johannesburg
Melbourne New Delhi, pp 531–630
5. Daly M, Tuft SJ, Munro PM (2005)
Acute corneal calcification following
chemical injury. Cornea 24:761–765
6. Huang Y, Meek KM, Mangat H et al
(1998) Acute calcification in alkali-
injured rabbit cornea treated with syn-
thetic inhibitor of metalloproteinases
(SIMP). Cornea 17:423–432
7. Knedel M, Haeckel R, Seidel D, Thiery
J, Vonderschmitt DJ, Hänseler E (1986)
Analytical performance of the random
access analyser Hitachi 737. A multi-
centre evaluation. J Clin Chem Clin
Biochem 31:409–432
8. Nevyas AS, Raber IM, Eagle RC Jr
et al (1987) Acute band keratopathy
following intracameral Viscoat.
Arch Ophthalmol 105:958–964
9. Schlötzer–Schrehardt U, Zagorski Z,
Holbach LM et al (1999) Corneal
stromal calcification after topical
steroid-phosphate therapy. Arch
Ophthalmol 117:1414–1418
10. Schrage NF, Schloßmacher B,
Aschenberner W et al (2001) Phosphate
buffer in alkali eye burns as
an inducer of experimental corneal
calcification. Burns 27:459–464
1014
